Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 08, 2023 16:05 ET
|
Matinas BioPharma Holdings, Inc.
FDA feedback on MAT2203 Phase 3 program supports a patient population in invasive aspergillosis with limited treatment options, acknowledges potential for LPAD pathway; composite superiority endpoint...
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
November 07, 2023 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies...
Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023
November 01, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular...
Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
October 11, 2023 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid...
Matinas BioPharma to Present at Two Investment Conferences in October 2023
September 28, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small...
Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek
September 27, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small...
Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
September 22, 2023 17:25 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small...
Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
September 06, 2023 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular...
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
August 22, 2023 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid...
Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 09, 2023 16:05 ET
|
Matinas BioPharma Holdings, Inc.
FDA indicated that approval of MAT2203 as a first-line treatment for invasive aspergillosis will require an adequately powered study with an active control group and an all-cause mortality...